← Oncology Approval Tracker

FDA DECISION ·

Voranigo

vorasidenib · Servier Pharmaceuticals

FDA approvalNew therapyGlioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma and a susceptible IDH1 or IDH2 mutation after surgery, including biopsy or partial or complete resection.

LAMPGEN ANALYSIS

Why it matters

The brain-penetrant IDH inhibitor adds a postoperative option for a defined grade 2 glioma population.

What research teams should watch

Preserve the molecular pathology and surgical history, and coordinate serial MRI review and liver enzyme monitoring.

PRIMARY RECORDS

Sources